Image-guided nanosystems for targeted delivery in cancer therapy

Current Medicinal Chemistry

Volumn 19, Issue 19, 2012, Pages 3230-3240

  Iyer, A K ^a   He, J ^b,c   Amiji, M M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug delivery; Image guided delivery; Liposomes; Multifunctional nanosystems; Personalized medicine; Polymeric nanoparticles; Theranostics; Tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; SMALL INTERFERING RNA;

CANCER CHEMOTHERAPY; CANCER GENE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ENDOCYTOSIS; FLUORESCENCE MICROSCOPY; GENE SILENCING; IMAGE GUIDED DRUG DELIVERY SYSTEM; IN VIVO STUDY; MOLECULAR IMAGING; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; REVIEW; RNA INTERFERENCE;

ANIMALS; DIAGNOSTIC IMAGING; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMAGERY (PSYCHOTHERAPY); NANOMEDICINE; NEOPLASMS;

EID: 84863657676     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800784685     Document Type: Review

References (152)

1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
2. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
3. Gupta, P.B.; Chaffer, C.L.; Weinberg, R.A. Cancer stem cells: mirage or reality? Nat. Med., 2009, 15(9), 1010-1012.
4. Al-Hajj, M.; Clarke, M.F. Self-renewal and solid tumor stem cells. Oncogene, 2004, 23(43), 7274-7282.
5. Martinez-Zaguilan, R.; Seftor, E.A.; Seftor, R.E.; Chu, Y.W.; Gillies, R.J.; Hendrix, M.J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis, 1996, 14(2), 176-186.
6. Gatenby, R.A.; Gawlinski, E.T. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res., 2003, 63(14), 3847-3854.
7. Asosingh, K.; De Raeve, H.; de Ridder, M.; Storme, G.A.; Willems, A.; Van Riet, I.; Van Camp, B.; Vanderkerken, K. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica, 2005, 90(6), 810-817.
8. Dang, C.V.; Lewis, B.C.; Dolde, C.; Dang, G.; Shim, H. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J. Bioenerg. Biomembr., 1997, 29(4), 345-354.
9. Vaupel, P.; Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev., 2007, 26(2), 225-239.
10. Milane, L.; Duan, Z.; Amiji, M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell. Int., 2011, 11, 3.
11. Dutour, A.; Leclers, D.; Monteil, J.; Paraf, F.; Charissoux, J.L.; Rousseau, R.; Rigaud, M. Non-invasive imaging correlates with histological and molecular characteristics of an osteosarcoma model: application for early detection and follow-up of MDR phenotype. Anticancer Res., 2007, 27(6B), 4171-4178.
12. Biedler, J.L. Genetic aspects of multidrug resistance. Cancer, 1992, 70(6 Suppl.), 1799-1809.
13. Jabr-Milane, L.S.; van Vlerken, L.E.; Yadav, S.; Amiji, M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev., 2008, 34(7), 592-602.
14. Donnenberg, V.S.; Donnenberg, A.D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J. Clin. Pharmacol., 2005, 45(8), 872-877.
15. Cahill, D.P.; Kinzler, K.W.; Vogelstein, B.; Lengauer, C. Genetic instability and darwinian selection in tumours. Trends Cell Biol., 1999, 9(12), M57-60.
16. Loeb, L.A.; Loeb, K.R.; Anderson, J.P. Multiple mutations and cancer. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(3), 776-781.
17. Rowinsky, E.K.; Chaudhry, V.; Forastiere, A.A.; Sartorius, S.E.; Ettinger, D.S.; Grochow, L.B.; Lubejko, B.G.; Cornblath, D.R.; Donehower, R.C. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J. Clin. Oncol., 1993, 11(10), 2010-2020.
18. Steinherz, L.J.; Steinherz, P.G.; Tan, C.T.; Heller, G.; Murphy, M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 1991, 266(12), 1672-1677.
19. Allen, T.M.; Cullis, P.R. Drug delivery systems: entering the mainstream. Science, 2004, 303(5665), 1818-1822.
20. Tseng, Y.C.; Mozumdar, S.; Huang, L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev., 2009, 61(9), 721-731.
21. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov., 2009, 8(2), 129-138.
22. Wulfkuhle, J.D.; Liotta, L.A.; Petricoin, E.F. Proteomic applications for the early detection of cancer. Nat. Rev. Cancer, 2003, 3(4), 267-275.
23. Ott, J.J.; Ullrich, A.; Miller, A.B. The importance of early symptom recognition in the context of early detection and cancer survival. Eur. J. Cancer, 2009, 45(16), 2743-2748.
24. Weissleder, R. Molecular imaging in cancer. Science, 2006, 312(5777), 1168-1171.
25. Massoud, T.F.; Gambhir, S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev., 2003, 17(5), 545-580.
26. Ntziachristos, V.; Chance, B. Probing physiology and molecular function using optical imaging: applications to breast cancer. Breast Cancer Res., 2001, 3(1), 41-46.
27. Tolmachev, V.; Orlova, A.; Nilsson, F.Y.; Feldwisch, J.; Wennborg, A.; Abrahmsen, L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin. Biol. Ther., 2007, 7(4), 555-568.
28. Jaffer, F.A.; Weissleder, R. Molecular imaging in the clinical arena. JAMA, 2005, 293(7), 855-862.
29. Iyer, A.K.; Lan, X.; Zhu, X.; Su, Y.; Feng, J.; Zhang, X.; Gao, D.; Seo, Y.; Vanbrocklin, H.F.; Broaddus, V.C.; Liu, B.; He, J. Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas. Cancer Res., 2011, 71(7), 2428-2432.
30. Yang, D.J.; Azhdarinia, A.; Wu, P.; Yu, D.F.; Tansey, W.; Kalimi, S.K.; Kim, E.E.; Podoloff, D.A. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother. Radiopharm., 2001, 16(1), 73-83.
31. Sumer, B.; Gao, J. Theranostic nanomedicine for cancer. Nanomedicine (Lond.), 2008, 3(2), 137-140.
32. Gross, S.; Piwnica-Worms, D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell, 2005, 7(1), 5-15.
33. Weissleder, R. Molecular imaging: exploring the next frontier. Radiology, 1999, 212(3), 609-614.
34. Corsten, M.F.; Hofstra, L.; Narula, J.; Reutelingsperger, C.P. Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res., 2006, 66(3), 1255-1260.
35. Mankoff, D.A.; O'Sullivan, F.; Barlow, W.E.; Krohn, K.A. Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad. Radiol., 2007, 14(4), 398-405.
36. Weissleder, R.; Pittet, M.J. Imaging in the era of molecular oncology. Nature, 2008, 452(7187), 580-589.
37. Semelka, R.C.; Armao, D.M.; Elias, J., Jr.; Huda, W. Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI. J. Magn. Reson. Imaging, 2007, 25(5), 900-909.
38. Aime, S.; Cabella, C.; Colombatto, S.; Geninatti Crich, S.; Gianolio, E.; Maggioni, F. Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J. Magn. Reson. Imaging, 2002, 16(4), 394-406.
39. Caravan, P.; Ellison, J.J.; McMurry, T.J.; Lauffer, R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev., 1999, 99(9), 2293-2352.
40. Kaneko, M.; Eguchi, K.; Ohmatsu, H.; Kakinuma, R.; Naruke, T.; Suemasu, K.; Moriyama, N. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology, 1996, 201(3), 798-802.
41. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev., 2001, 46(1-3), 169-185.
42. Brenner, D.J.; Hall, E.J. Computed tomography-an increasing source of radiation exposure. N. Engl. J. Med., 2007, 357(22), 2277-2284.
43. Aberle, D.R.; Adams, A.M.; Berg, C.D.; Black, W.C.; Clapp, J.D.; Fagerstrom, R.M.; Gareen, I.F.; Gatsonis, C.; Marcus, P.M.; Sicks, J.D. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med., 2011, 365(5), 395-409.
44. Bangerter, M.; Kotzerke, J.; Griesshammer, M.; Elsner, K.; Reske, S.N.; Bergmann, L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta. Oncol., 1999, 38(6), 799-804.
45. Keidar, Z.; Israel, O.; Krausz, Y. SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin. Nucl. Med., 2003, 33(3), 205-218.
46. Berger, F.; Gambhir, S. Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer. Breast Cancer Res., 2001, 3(1), 28-35.
47. Phelps, M. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med., 2000, 41(4), 661-681.
48. Pan, D.; Gambhir, S.; Toyokuni, T.; Iyer, M.; Acharya, N.; Phelps, M.; Barrio, J. Rapid synthesis of a 5-fluorinated oligodeoxy-nucleotide: a model antisense probe for use in imaging with positron emission tomography (PET). Bioorg. Med. Chem. Lett., 1998, 8(11), 1317-1320.
49. Wahl, R.L.; Quint, L.E.; Greenough, R.L.; Meyer, C.R.; White, R.I.; Orringer, M.B. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology, 1994, 191(2), 371-377.
50. Nabi, H.A.; Zubeldia, J.M. Clinical applications of (18)F-FDG in oncology. J. Nucl. Med. Technol., 2002, 30(1), 3-9; quiz 10-11.
51. Gambhir, S.S.; Czernin, J.; Schwimmer, J.; Silverman, D.H.; Coleman, R.E.; Phelps, M.E. A tabulated summary of the FDG PET literature. J. Nucl. Med., 2001, 42(5 Suppl.), 1S-93S.
52. Mitterhauser, M.; Toegel, S.; Wadsak, W.; Lanzenberger, R.; Mien, L.; Kuntner, C.; Wanek, T.; Eidherr, H.; Ettlinger, D.; Viernstein, H. Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nucl. Med. Biol., 2007, 34(4), 391-397.
53. Maecke, H.; Hofmann, M.; Haberkorn, U. 68Ga-labeled peptides in tumor imaging. J. Nucl. Med., 2005, 46(1 suppl), 172S-178S.
54. Funk, T.; Despres, P.; Barber, W.C.; Shah, K.S.; Hasegawa, B.H. A multipinhole small animal SPECT system with submillimeter spatial resolution. Med. Phys., 2006, 33(5), 1259-1268.
55. Banerjee, S.; Pillai, A.; Raghavan, M.; Ramamoorthy, N. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin. Nucl. Med., 2001, 31, 260-277.
56. Hamoudeh, M.; Kamleh, M.A.; Diab, R.; Fessi, H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv. Drug Deliv. Rev., 2008, 60(12), 1329-1346.
57. Chow, T.H.; Lin, Y.Y.; Hwang, J.J.; Wang, H.E.; Tseng, Y.L.; Pang, V.F.; Liu, R.S.; Lin, W.J.; Yang, C.S.; Ting, G. Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J. Nucl. Med., 2009, 50(12), 2073-2081.
58. Ting, G.; Chang, C.H.; Wang, H.E. Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res., 2009, 29(10), 4107-4118.
59. Jones, E.F.; He, J.; VanBrocklin, H.F.; Franc, B.L.; Seo, Y. Nanoprobes for medical diagnosis: current status of nanotechnology in molecular imaging. Curr. Nanosci., 2008, 4(1), 17-29.
60. Mariani, G.; Bruselli, L.; Kuwert, T.; Kim, E.E.; Flotats, A.; Israel, O.; Dondi, M.; Watanabe, N. A review on the clinical uses of SPECT/CT. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(10), 1959-1985.
61. Chatziioannou, A. Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. Proc. Am. Thorac. Soc., 2005, 2, 533-536.
62. Cherry, S. Multimodality imaging: beyond PET/CT and SPECT/CT. Semin. Nucl. Med., 2009, 39, 348-353.
63. Judenhofer, M.S.; Wehrl, H.F.; Newport, D.F.; Catana, C.; Siegel, S.B.; Becker, M.; Thielscher, A.; Kneilling, M.; Lichy, M.P.; Eichner, M.; Klingel, K.; Reischl, G.; Widmaier, S.; Rocken, M.; Nutt, R.E.; Machulla, H.J.; Uludag, K.; Cherry, S.R.; Claussen, C.D.; Pichler, B.J. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med., 2008, 14(4), 459-465.
64. Kaijzel, E.L.; van der Pluijm, G.; Lowik, C.W. Whole-body optical imaging in animal models to assess cancer development and progression. Clin. Cancer Res., 2007, 13(12), 3490-3497.
65. Choy, G.; Choyke, P.; Libutti, S.K. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol. Imaging, 2003, 2(4), 303-312.
66. Sokolov, K.; Follen, M.; Aaron, J.; Pavlova, I.; Malpica, A.; Lotan, R.; Richards-Kortum, R. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res., 2003, 63(9), 1999-2004.
67. Moore, R.L. Treatment of an infant with paroxysmal auricular tachycardia. Pediatrics, 1948, 2(3), 266-271.
68. Graves, E.E.; Weissleder, R.; Ntziachristos, V. Fluorescence molecular imaging of small animal tumor models. Curr. Mol. Med., 2004, 4(4), 419-430.
69. Hilderbrand, S.A.; Weissleder, R. Near-infrared fluorescence: application to in vivo molecular imaging. Curr. Opin. Chem. Biol., 2010, 14(1), 71-79.
70. Potineni, A.; Lynn, D.M.; Langer, R.; Amiji, M.M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J. Control. Release, 2003, 86(2-3), 223-234.
71. Susa, M.; Iyer, A.K.; Ryu, K.; Choy, E.; Hornicek, F.J.; Mankin, H.; Milane, L.; Amiji, M.M.; Duan, Z. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One, 2010, 5(5), e10764.
72. van Vlerken, L.E.; Vyas, T.K.; Amiji, M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res., 2007, 24(8), 1405-1414.
73. Harris, J.M.; Martin, N.E.; Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet., 2001, 40(7), 539-551.
74. Tiwari, S.B.; Amiji, M.M. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J. Nanosci. Nanotechnol., 2006, 6(9-10), 3215-3221.
75. Kim, K.; Kim, J.H.; Park, H.; Kim, Y.S.; Park, K.; Nam, H.; Lee, S.; Park, J.H.; Park, R.W.; Kim, I.S.; Choi, K.; Kim, S.Y.; Kwon, I.C. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release, 2010, 146(2), 219-227.
76. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1(1), 27-31.
77. Ghosh, K.; Thodeti, C.K.; Dudley, A.C.; Mammoto, A.; Klagsbrun, M.; Ingber, D.E. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(32), 11305-11310.
78. Greish, K.; Fang, J.; Inutsuka, T.; Nagamitsu, A.; Maeda, H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet., 2003, 42(13), 1089-1105.
79. Padera, T.P.; Kadambi, A.; di Tomaso, E.; Carreira, C.M.; Brown, E.B.; Boucher, Y.; Choi, N.C.; Mathisen, D.; Wain, J.; Mark, E.J.; Munn, L.L.; Jain, R.K. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science, 2002, 296(5574), 1883-1886.
80. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46, 6387-6392.
81. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 2000, 65(1-2), 271-284.
82. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219(4587), 983-985.
83. Dvorak, H.F.; Nagy, J.A.; Feng, D.; Brown, L.F.; Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol., 1999, 237, 97-132.
84. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219(4587), 983-985.
85. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul., 2001, 41, 189-207.
86. Iyer, A.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today, 2006, 11(17-18), 812-818.
87. Maeda, H.; Bharate, G.Y.; Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm., 2009, 71(3), 409-419.
88. Duncan, R.; Ringsdorf, H.; Satchi-Fainaro, R. Polymer therapeutics-polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities. J. Drug Target., 2006, 14(6), 337-341.
89. Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release, 2008, 126(3), 187-204.
90. Danhier, F.; Feron, O.; Préat, V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release, 2010, 148(2), 135-146.
91. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D.A.; Torchilin, V.P.; Jain, R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res., 1995, 55(17), 3752-3756.
92. Davis, S.S. Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol., 1997, 15(6), 217-224.
93. Kuszyk, B.S.; Corl, F.M.; Franano, F.N.; Bluemke, D.A.; Hofmann, L.V.; Fortman, B.J.; Fishman, E.K. Tumor transport physiology: implications for imaging and imaging-guided therapy. Am. J. Roentgenol., 2001, 177(4), 747-753.
94. Marcucci, F.; Lefoulon, F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov. Today, 2004, 9(5), 219-228.
95. Milane, L.; Duan, Z.F.; Amiji, M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine, 2011, 7(4), 435-444.
96. Milane, L.; Duan, Z.; Amiji, M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol. Pharm., 2011, 8(1), 185-203.
97. Werner, M.E.; Karve, S.; Sukumar, R.; Cummings, N.D.; Copp, J.A.; Chen, R.C.; Zhang, T.; Wang, A.Z. Folate-targeted nanoparticle delivery of chemo-and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials, 2011, 32(33), 8548-8554.
98. Rihova, B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev., 1998, 29(3), 273-289.
99. Lue, N.; Ganta, S.; Hammer, D.X.; Mujat, M.; Stevens, A.E.; Harrison, L.; Ferguson, R.D.; Rosen, D.; Amiji, M.; Iftimia, N. Preliminary evaluation of a nanotechnology-based approach for the more effective diagnosis of colon cancers. Nanomedicine (Lond.), 2010, 5(9), 1467-1479.
100. Farokhzad, O.C.; Karp, J.M.; Langer, R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv., 2006, 3(3), 311-324.
101. Iyer, A.K.; Su, Y.; Feng, J.; Lan, X.; Zhu, X.; Liu, Y.; Gao, D.; Seo, Y.; Vanbrocklin, H.F.; Courtney Broaddus, V.; Liu, B.; He, J. The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials, 2011, 32(10), 2605-2613.
102. Benyettou, F.; Lalatonne, Y.; Chebbi, I.; Di Benedetto, M.; Serfaty, J.M.; Lecouvey, M.; Motte, L. A multimodal magnetic resonance imaging nanoplatform for cancer theranostics. Phys. Chem. Chem. Phys., 2011, 13(21), 10020-10027.
103. O'Brien, M.E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D.G.; Tomczak, P.; Ackland, S.P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol., 2004, 15(3), 440-449.
104. Otsuka, H.; Nagasaki, Y.; Kataoka, K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev., 2003, 55(3), 403-419.
105. Maeda, H.; Matsumura, Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv. Drug. Deliv. Rev., 2011, 63(3), 129-130.
106. van Vlerken, L.E.; Duan, Z.; Little, S.R.; Seiden, M.V.; Amiji, M.M. Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol. Pharm., 2008, 5(4), 516-526.
107. Cao, N.; Cheng, D.; Zou, S.; Ai, H.; Gao, J.; Shuai, X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials, 2011, 32(8), 2222-2232.
108. Bhavsar, M.D.; Amiji, M.M. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control. Release, 2007, 119(3), 339-348.
109. Uhrich, K.E.; Cannizzaro, S.M.; Langer, R.S.; Shakesheff, K.M. Polymeric systems for controlled drug release. Chem. Rev., 1999, 99(11), 3181-3198.
110. Dillen, K.; Vandervoort, J.; Van den Mooter, G.; Ludwig, A. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int. J. Pharm., 2006, 314(1), 72-82.
111. Ghotbi, Z.; Haddadi, A.; Hamdy, S.; Hung, R.W.; Samuel, J.; Lavasanifar, A. Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. J. Drug Target., 2011, 19(4), 281-292.
112. Choi, C.H.; Alabi, C.A.; Webster, P.; Davis, M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(3), 1235-1240.
113. Choi, K.Y.; Chung, H.; Min, K.H.; Yoon, H.Y.; Kim, K.; Park, J.H.; Kwon, I.C.; Jeong, S.Y. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials, 2010, 31(1), 106-114.
114. Pecot, C.V.; Calin, G.A.; Coleman, R.L.; Lopez-Berestein, G.; Sood, A.K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer, 2011, 11(1), 59-67.
115. Torchilin, V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng., 2006, 8, 343-375.
116. Panyam, J.; Labhasetwar, V. Targeting intracellular targets. Curr. Drug. Deliv., 2004, 1(3), 235-247.
117. Devalapally, H.; Duan, Z.; Seiden, M.V.; Amiji, M.M. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer. Res., 2008, 14(10), 3193-3203.
118. van Vlerken, L.E.; Duan, Z.; Seiden, M.V.; Amiji, M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res., 2007, 67(10), 4843-4850.
119. Daniel, M.C.; Astruc, D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem. Rev., 2004, 104(1), 293-346.
120. Sahoo, S.K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today, 2003, 8(24), 1112-1120.
121. McCarthy, J.R.; Weissleder, R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev., 2008, 60(11), 1241-1251.
122. Gindy, M.E.; Prud'homme, R.K. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin. Drug Deliv., 2009, 6(8), 865-878.
123. Koning, G.A.; Krijger, G.C. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med. Chem., 2007, 7(4), 425-440.
124. Lammers, T.; Subr, V.; Peschke, P.; Kuhnlein, R.; Hennink, W.E.; Ulbrich, K.; Kiessling, F.; Heilmann, M.; Debus, J.; Huber, P.E.; Storm, G. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. B r. J. Cancer, 2008, 99(6), 900-910.
125. Iyer, A.K.; Greish, K.; Fang, J.; Murakami, R.; Maeda, H. High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor. Biomaterials, 2007, 28(10), 1871-1881.
126. Wang, F.; Bronich, T.K.; Kabanov, A.V.; Rauh, R.D.; Roovers, J. Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon- caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier. Bioconjug. Chem., 2005, 16(2), 397-405.
127. Gillies, E.R.; Frechet, J.M. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today, 2005, 10(1), 35-43.
128. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2(12), 751-760.
129. Kim, J.; Piao, Y.; Hyeon, T. Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy. Chem. Soc. Rev., 2009, 38(2), 372-390.
130. Wijagkanalan, W.; Kawakami, S.; Hashida, M. Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm. Res., 2011, 28(7), 1500-1519.
131. Liu, M.; Frechet, J.M. Designing dendrimers for drug delivery. Pharm. Sci. Technol. Today, 1999, 2(10), 393-401.
132. Gabizon, A.; Chisin, R.; Amselem, S.; Druckmann, S.; Cohen, R.; Goren, D.; Fromer, I.; Peretz, T.; Sulkes, A.; Barenholz, Y. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer, 1991, 64(6), 1125-1132.
133. Mikhaylova, M.; Stasinopoulos, I.; Kato, Y.; Artemov, D.; Bhujwalla, Z.M. Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther., 2009, 16(3), 217-226.
134. Magin, R.L.; Wright, S.M.; Niesman, M.R.; Chan, H.C.; Swartz, H.M. Liposome delivery of NMR contrast agents for improved tissue imaging. Magn. Reson. Med., 1986, 3(3), 440-447.
135. Mackiewicz, N.; Gravel, E.; Garofalakis, A.; Ogier, J.; John, J.; Dupont, D.M.; Gombert, K.; Tavitian, B.; Doris, E.; Duconge, F. Tumor-targeted polydiacetylene micelles for in vivo imaging and drug delivery. Small, 2011, 7(19), 2786-2792.
136. Li, X.; Qian, Y.; Liu, T.; Hu, X.; Zhang, G.; You, Y.; Liu, S. Amphiphilic multiarm star block copolymer-based multifunctional unimolecular micelles for cancer targeted drug delivery and MR imaging. Biomaterials, 2011, 32(27), 6595-6605.
137. Feng, X.; Lv, F.; Liu, L.; Tang, H.; Xing, C.; Yang, Q.; Wang, S. Conjugated polymer nanoparticles for drug delivery and imaging. ACS Appl. Mater. Interfaces, 2010, 2(8), 2429-2435.
138. Goldberg, M.; Mahon, K.; Anderson, D. Combinatorial and rational approaches to polymer synthesis for medicine. Adv. Drug Deliv. Rev., 2008, 60(9), 971-978.
139. Abeylath, S.C.; Ganta, S.; Iyer, A.K.; Amiji, M. Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. Acc. Chem. Res., 2011, 44(10), 1009-1017.
140. Green, J.J.; Langer, R.; Anderson, D.G. A Combinatorial polymer library approach yields insight into nonviral gene delivery. Acc. Chem. Res., 2008, 41(6), 749-759.
141. Kim, S.H.; Jeong, J.H.; Lee, S.H.; Kim, S.W.; Park, T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release, 2008, 129(2), 107-116.
142. Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release, 2001, 74(1-3), 47-61.
143. Yu, M.K.; Kim, D.; Lee, I.H.; So, J.S.; Jeong, Y.Y.; Jon, S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small, 2011, 7(15), 2241-2249.
144. Santra, S.; Kaittanis, C.; Grimm, J.; Perez, J.M. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small, 2009, 5(16), 1862-1868.
145. Reddy, G.R.; Bhojani, M.S.; McConville, P.; Moody, J.; Moffat, B.A.; Hall, D.E.; Kim, G.; Koo, Y.E.; Woolliscroft, M.J.; Sugai, J.V.; Johnson, T.D.; Philbert, M.A.; Kopelman, R.; Rehemtulla, A.; Ross, B.D. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res., 2006, 12(22), 6677-6686.
146. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P.W.; Langer, R.; Farokhzad, O.C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett., 2007, 7(10), 3065-3070.
147. Koo, H.; Lee, H.; Lee, S.; Min, K.H.; Kim, M.S.; Lee, D.S.; Choi, Y.; Kwon, I.C.; Kim, K.; Jeong, S.Y. In vivo tumor diagnosis and photodynamic therapy via tumoral pH-responsive polymeric micelles. Chem. Commun. (Camb.), 2010, 46(31), 5668-5670.
148. Shegokar, R.; Al Shaal, L.; Mishra, P.R. SiRNA delivery: challenges and role of carrier systems. Pharmazie, 2011, 66(5), 313-318.
149. Medarova, Z.; Pham, W.; Farrar, C.; Petkova, V.; Moore, A. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med., 2007, 13(3), 372-377.
150. Kumar, M.; Yigit, M.; Dai, G.; Moore, A.; Medarova, Z. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res., 2010, 70(19), 7553-7561.
151. Susa, M.; Iyer, A.K.; Ryu, K.; Hornicek, F.J.; Mankin, H.; Amiji, M.M.; Duan, Z. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer, 2009, 9, 399.
152. Huh, M.S.; Lee, S.Y.; Park, S.; Lee, S.; Chung, H.; Choi, Y.; Oh, Y.K.; Park, J.H.; Jeong, S.Y.; Choi, K.; Kim, K.; Kwon, I.C. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J. Control. Release, 2010, 144(2), 134-143.